Does the aldosterone: Renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study

BMC Cardiovascular Disorders

Volumn 7, Issue , 2007, Pages

  Parthasarathy, Hari K ^a   Alhashmi, Khamis ^b   McMahon, Alex D ^c   Struthers, Allan D ^a   Connell, John M C ^b   McInnes, Gordon T ^b   Ford, Ian ^c   MacDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

18 OXOHYDROCORTISONE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; POTASSIUM; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RENIN; SPIRONOLACTONE; STEROID;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EXERCISE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTHESIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTION; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; QT DISPERSION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; BLOOD; COMPARATIVE STUDY;

ALDOSTERONE; BENDROFLUMETHIAZIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; HYPERTENSION; RENIN; SPIRONOLACTONE;

EID: 34250797919     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-7-14     Document Type: Article

References (35)

1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Jama 2002 288 2981-2997 10.1001/ jama.288.23.2981 12479763
2. Hiramatsu K Yamada T Yukimura Y Komiya I Ichikawa K Ishihara M Nagata H Izumiyama T A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients Arch Intern Med 1981 141 1589-1593 10.1001/archinte.141.12.1589 7030245
3. Gordon RD Mineralocorticoid hypertension Lancet 1994 344 240-243 10.1016/ S0140-6736(94)93003-1 7913162
4. Lim PO Dow E Brennan G Jung RT MacDonald TM High prevalence of primary aldosteronism in the Tayside hypertension clinic population J Hum Hypertens 2000 14 311-315 10.1038/sj.jhh.1001013 10822317
5. Lim PO Rodgers P Cardale K Watson AD MacDonald TM Potentially high prevalence of primary aldosteronism in a primary-care population Lancet 1999 353 40 10.1016/S0140-6736(05)74868-6 10023956
6. Lim PO Macdonald TM Holloway C Friel E Anderson NH Dow E Jung RT Davies E Fraser R Connell JM Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio J Clin Endocrinol Metab 2002 87 4398-4402 10.1210/jc.2001-012070 12213905
7. Lim PO Farquharson CA Shiels P Jung RT Struthers AD MacDonald TM Adverse cardiac effects of salt with fludrocortisone in hypertension Hypertension 2001 37 856-861 11244008
8. Young W Incidence and workup of primary aldosteronism at the Mayo Clinic: Brisbane. 1999
9. Gordon R Incidence and workup of primary aldosteronism: Greenslopes Hospital series: Brisbane. 1999
10. Van Heerden J A AFC Outcomes of surgery for primary aldosteronism: An instituinal experience: Brisbane. 1999
11. Brown JJ Davies DL Ferriss JB Fraser R Haywood E Lever AF Robertson JI Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin Br Med J 1972 2 729-734 1788474 4338668
12. Ghose RP Hall PM Bravo EL Medical management of aldosterone-producing adenomas Ann Intern Med 1999 131 105-108 10419425
13. Lim PO Young WF MacDonald TM A review of the medical treatment of primary aldosteronism J Hypertens 2001 19 353-361 10.1097/ 00004872-200103000-00001 11288803
14. Adlin EV Marks AD Channick BJ Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity Arch Intern Med 1972 130 855-858 10.1001/archinte.130.6.855 5082465
15. Gwinup G Steinberg T Differential response to thiazides and spironolactone in primary aldosteronism Arch Intern Med 1967 120 436-443 10.1001/archinte.120.4.436 6058098
16. Lim PO Jung RT MacDonald TM Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study Br J Clin Pharmacol 1999 48 756-760 10.1046/ j.1365-2125.1999.00070.x 10594479
17. Gallay BJ Ahmad S Xu L Toivola B Davidson RC Screening for primary aldosteronism without discontinuing hypertensive medications: Plasma aldosterone-renin ratio Am J Kidney Dis 2001 37 699-705 11273868
18. O'Brien E Waeber B Parati G Staessen J Myers MG Blood pressure measuring devices: Recommendations of the European Society of Hypertension Bmj 2001 322 531-536 1119736 11230071 10.1136/bmj.322.7285.531
19. Suwaidi JA Hamasaki S Higano ST Nishimura RA Holmes DR Jr. Lerman A Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction Circulation 2000 101 948-954 10704159
20. Elming H Holm E Jun L Torp-Pedersen C Kober L Kircshoff M Malik M Camm J The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens Eur Heart J 1998 19 1391-1400 10.1053/euhj.1998.1094 9792266
21. Nolan J Batin PD Andrews R Lindsay SJ Brooksby P Mullen M Baig W Flapan AD Cowley A Prescott RJ Neilson JM Fox KA Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart) Circulation 1998 98 1510-1516 9769304
22. Pitt B Zannad F Remme WJ Cody R Castaigne A Perez A Palensky J Wittes J The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 1999 341 709-717 10.1056/NEJM199909023411001 10471456
23. Yee KM Pringle SD Struthers AD Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure J Am Coll Cardiol 2001 37 1800-1807 10.1016/ S0735-1097(01)01243-8 11401114
24. Farquharson CA Struthers AD Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure Circulation 2000 101 594-597 10673249
25. Lim PO Donnan PT MacDonald TM Aldosterone to renin ratio as a determinant of exercise blood pressure response in hypertensive patients J Hum Hypertens 2001 15 119-123 10.1038/sj.jhh.1001138 11317191
26. Zannad F Alla F Dousset B Perez A Pitt B Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 2000 102 2700-2706 11094035
27. Flack JM Peters R Shafi T Alrefai H Nasser SA Crook E Prevention of hypertension and its complications: Theoretical basis and guidelines for treatment J Am Soc Nephrol 2003 14 S92-8 10.1097/ 01.ASN.0000070142.14843.8E 12819310
28. Gandhi S Santiesteban H Resistant hypertension. Suggestions for dealing with the problem Postgrad Med 1996 100 97-102, 107-8 8858085
29. Gordon RD Stowasser M Tunny TJ Klemm SA Rutherford JC High incidence of primary aldosteronism in 199 patients referred with hypertension Clin Exp Pharmacol Physiol 1994 21 315-318 7923898
30. Isles CG Walker LM Beevers GD Brown I Cameron HL Clarke J Hawthorne V Hole D Lever AF Robertson JW Mortality in patients of the Glasgow Blood Pressure Clinic J Hypertens 1986 4 141-156 10.1097/ 00004872-198604000-00003 3711657
31. Struthers AD Aldosterone: Cardiovascular assault Am Heart J 2002 144 S2-7 10.1067/mhj.2002.129969 12422134
32. Brilla CG Matsubara LS Weber KT Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism J Mol Cell Cardiol 1993 25 563-575 10.1006/ jmcc.1993.1066 8377216
33. Sato A Funder JW Saruta T Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis Am J Hypertens 1999 12 867-873 10.1016/ S0895-7061(99)00066-7 10509543
34. Pitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 1309-1321 10.1056/NEJMoa030207 12668699
35. Farquharson CA Struthers AD Aldosterone induces acute endothelial dysfunction in vivo in humans: Evidence for an aldosterone-induced vasculopathy Clin Sci (Lond) 2002 103 425-431 12241543